A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Daiichi Sankyo131 sites in 5 countries367 target enrollmentMay 2014

ConditionsAML

InterventionsQuizartinib Salvage Chemotherapy

DrugsQuizartinib Salvage Chemotherapy

Overview

Phase: Phase 3
Intervention: Quizartinib
Conditions: AML
Sponsor: Daiichi Sankyo
Enrollment: 367
Locations: 131
Primary Endpoint: Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy
Status: Completed
Last Updated: 5 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy.

Registry

clinicaltrials.gov

Start Date

May 2014

End Date

September 8, 2020

Last Updated

5 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Daiichi Sankyo

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Provision of written informed consent approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) with privacy language in accordance with national regulations (e.g., Health Insurance Portability and Accountability Act \[HIPAA\] authorization for United States \[US\] sites) prior to any study related procedures, including withdrawal of prohibited medications if applicable.
•Age ≥ 18 years or the minimum legal adult age (whichever is greater) at the time of Informed consent.
•Morphologically documented primary Acute Myeloid Leukemia (AML) or AML secondary to Myelodysplastic Syndrome (MDS), as defined by World Health Organization (WHO) criteria, as determined by pathology review at the study site.
•In first relapse (with duration of remission of 6 months or less) or refractory after prior therapy, with or without HSCT. Induction therapy must have included at least 1 cycle of an anthracycline/mitoxantrone-containing induction block at a standard dose.
•Presence of the FLT3-ITD activating mutation in bone marrow or peripheral blood (allelic ratio as determined by a central laboratory with a cutoff of ≥3% FLT3-ITD/total FLT3). If a specimen has been sent for FLT3-ITD testing at the central laboratory but the subject requires treatment for AML before the central FLT3-ITD test result is available, a local test result may be acceptable for randomization after consultation with the Medical Monitor.
•Eligibility for pre-selected salvage chemotherapy, according to the Investigator's assessment.
•Eastern Cooperative Oncology Group (ECOG) performance score 0-
•Discontinuation of prior AML treatment before the start of study treatment (except hydroxyurea or other treatment to control leukocytosis) for at least 2 weeks for cytotoxic agents, or for at least 5 half-lives for non cytotoxic agents.
•Serum creatinine ≤1.5×upper limit of normal (ULN), or glomerular filtration rate \>25 mL/min, as calculated with the Cockcroft-Gault formula.
•Serum potassium, magnesium, and calcium (serum calcium corrected for hypoalbuminemia) within institutional normal limits. Subjects with electrolytes outside the normal range will be eligible if these values are corrected upon retesting following any necessary supplementation.

Exclusion Criteria

•Acute Promyelocytic Leukemia (AML subtype M3).
•AML secondary to prior chemotherapy for other neoplasms, except AML secondary to prior Myelodysplastic Syndrome (MDS).
•History of another malignancy, unless the candidate has been disease-free for at least 5 years.
•Persistent, clinically significant \> Grade 1 non-hematologic toxicity from prior AML therapy.
•Clinically significant graft versus host disease (GVHD) or GVHD requiring initiation of treatment or treatment escalation within 21 days, and/or \> Grade 1 persistent or clinically significant non hematologic toxicity related to HSCT.
•History of or current, central nervous system involvement with AML.
•Clinically significant coagulation abnormality, such as disseminated intravascular coagulation.
•Prior treatment with quizartinib or participated in a prior quizartinib study.
•Prior treatment with a FLT3 targeted therapy including sorafenib or investigational FLT3 inhibitors (not including the multi-kinase inhibitor, midostaurin).
•Major surgery within 4 weeks prior to screening.

Arms & Interventions

Quizartinib

Participants who were randomized to receive 20 or 30 mg quizartinib tablets administered orally once daily.

Intervention: Quizartinib

Salvage chemotherapy

Participants who were randomized to receive salvage chemotherapy, such as low dose cytarabine (LoDAC); mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC); or fludarabine, cytarabine, and granulocyte colony stimulating factor (G-CSF) with idarubicin (FLAG-IDA), were administered during 28-day cycles.

Intervention: Salvage Chemotherapy

Outcomes

Primary Outcomes

Overall Survival in Participants That Received Quizartinib Versus Salvage Chemotherapy

Time Frame: At approximately 3 years 9 months

Overall Survival is defined as the time (in weeks) from the date of randomization to the date of death due to any cause. Median and quartiles are calculated using the Kaplan-Meier method.